Ads
related to: liver cancer treatment nexavar- uHCC Treatment Option
Patients: Learn More About A
Hepatocellular Carcinoma Treatment.
- uHCC Patient Information
Recently Diagnosed With uHCC?
Learn More About A Treatment Option
- Plan for uHCC Treatment
Diagnosis Can Be A Shock. Learn
How To Prepare For uHCC Treatment.
- Talk To Your Doctor
Learn How To Start The Conversation
About A uHCC Treatment Option.
- Patient & Caregiver Info
Learn More About uHCC & A
Treatment Option That Could Help.
- Patient & Caregiver Site
See Resources & Financial Support
For uHCC Patients & Caregivers.
- uHCC Treatment Option
Search results
Results From The WOW.Com Content Network
Sorafenib, sold under the brand name Nexavar, [3] is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
Sorafenib, co-developed and co-marketed with Bayer and sold under the trade name Nexavar, is a drug approved in the United States for the treatment of advanced renal cell carcinoma (kidney cancer) in 2005, and for the treatment of inoperable hepatocellular carcinoma, the most common form of liver cancer, in 2007. [7] [8] Sorafenib has also been ...
The extended follow-up further confirmed the favorable benefit-to-risk profile of C+R, supporting it as a new first-line treatment option for uHCC. About Hepatocellular Carcinoma. Worldwide each year more than 800,000 people are diagnosed with liver cancer and the disease is the cause of more than 830,000 deaths.
Estimates based on most recent data suggest that each year there are 841,000 new liver cancer diagnoses and 782,000 deaths across the globe. [55] Liver cancer is the most common cancer in Egypt, the Gambia, Guinea, Mongolia, Cambodia, and Vietnam. [55] In terms of gender breakdown, globally liver cancer is more common in men than in women. [43 ...
Consultant interventional radiologist Dr Brian Stedman said his team had performed 300 procedures in 100 patients whose form of eye cancer known as ocular melanoma had spread to the liver, called ...
Systemic therapy for HCC is indicated in BCLC stage C disease, in which cancer has spread beyond the liver. It is also indicated in BCLC stage B disease with tumor progression after local treatments. [6] In 2007, sorafenib, an oral multikinase inhibitor, was the first systemic agent approved for first-line treatment of advanced HCC. [75]
Ads
related to: liver cancer treatment nexavarwiserlifestyles.com has been visited by 100K+ users in the past month